Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Pharmacogenetics & Genomics

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FPC.0000000000000309PMID 28961156
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis

  2017cited by this paper
• CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study.

  2016cited by this paper
• Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.

  2016cited by this paper
• A Coding Variant in RARG Confers Susceptibility to Anthracycline-Induced Cardiotoxicity in Childhood Cancer

  2015cited by this paper
• Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.

  2015cited by this paper
• Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia

  2015cited by this paper
• The Reactome pathway Knowledgebase

  2015cited by this paper
• Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients

  2015cited by this paper
• PON-P2: Prediction Method for Fast and Reliable Identification of Harmful Variants

  2015cited by this paper
• Rare-variant association analysis: study designs and statistical tests.

  2014cited by this paper
• Gene Ontology Consortium: going forward

  2014cited by this paper
• Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group.

  2014cited by this paper
• PredictSNP: Robust and Accurate Consensus Classifier for Prediction of Disease-Related Mutations

  2014cited by this paper
• Hypoxia-inducible factor 1-induced G protein-coupled receptor 35 expression is an early marker of progressive cardiac remodelling.

  2014cited by this paper
• Role of the Renin-Angiotensin-Aldosterone System and the Glutathione S-Transferase Mu, Pi and Theta Gene Polymorphisms in Cardiotoxicity after Anthracycline Chemotherapy for Breast Carcinoma

  2013cited by this paper
• A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor

  2013cited by this paper
• Genetic susceptibility to anthracycline‐related congestive heart failure in survivors of haematopoietic cell transplantation

  2013cited by this paper
• Data, information, knowledge and principle: back to metabolism in KEGG

  2013cited by this paper
• Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia

  2013cited by this paper
• Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children

  2013cited by this paper
• Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms.

  2013cited by this paper
• The Reactome pathway knowledgebase

  2013cited by this paper
• Rare and common variants: twenty arguments

  2012cited by this paper
• The relationship between changes in functional cardiac parameters following anthracycline therapy and carbonyl reductase 3 and glutathione S transferase Pi polymorphisms

  2012cited by this paper
• Clinical and genetic determinants of anthracycline-induced cardiac iron accumulation.

  2012cited by this paper
• zCall: a rare variant caller for array-based genotyping: Genetics and population analysis

  2012cited by this paper
• Five years of GWAS discovery.

  2012cited by this paper
• Optimal tests for rare variant effects in sequencing association studies.

  2012cited by this paper
• Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.

  2012cited by this paper
• High risk of symptomatic cardiac events in childhood cancer survivors.

  2012cited by this paper
• ABCC1 polymorphisms in anthracycline‐induced cardiotoxicity in childhood acute lymphoblastic leukaemia

  2012cited by this paper
• Lysophosphatidic acid in atherosclerotic diseases

  2012cited by this paper
• Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies.

  2012cited by this paper
• Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

  2012cited by this paper
• Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group

  2012cited by this paper
• Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer

  2011cited by this paper
• Identification of genes related to heart failure using global gene expression profiling of human failing myocardium.

  2010cited by this paper
• Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

  2010cited by this paper
• Uncovering the roles of rare variants in common disease through whole-genome sequencing

  2010cited by this paper
• A method and server for predicting damaging missense mutations

  2010cited by this paper
• Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions*

  2009cited by this paper
• Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

  2009cited by this paper
• Functional annotations improve the predictive score of human disease‐related mutations in proteins

  2009cited by this paper
• Automated inference of molecular mechanisms of disease from amino acid substitutions

  2009cited by this paper
• Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21

  2009cited by this paper
• Finding the missing heritability of complex diseases

  2009cited by this paper
• Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood

  2009cited by this paper
• Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancer

  2008cited by this paper
• Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data.

  2008cited by this paper
• Application of machine learning algorithms to predict coronary artery calcification with a sibship‐based design

  2008cited by this paper
• Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

  2008cited by this paper
• F-SNP: computationally predicted functional SNPs for disease association studies

  2007cited by this paper
• PLINK: a tool set for whole-genome association and population-based linkage analyses.

  2007cited by this paper
• GenABEL: an R library for genome-wide association analysis

  2007cited by this paper
• Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35*

  2006cited by this paper
• Principal components analysis corrects for stratification in genome-wide association studies

  2006cited by this paper
• Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.

  2005cited by this paper
• NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity

  2005cited by this paper
• DAVID: Database for Annotation, Visualization, and Integrated Discovery

  2003cited by this paper
• DAVID: Database for Annotation, Visualization, and Integrated Discovery

  2003cited by this paper
• Signalling: Seven-transmembrane receptors

  2002cited by this paper
• Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina?

  2002cited by this paper
• Candidate-gene approaches for studying complex genetic traits: practical considerations

  2002cited by this paper
• Galpha(12/13) mediates alpha(1)-adrenergic receptor-induced cardiac hypertrophy.

  2002cited by this paper
• Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats.

  2002cited by this paper
• Gα12/13 Mediates α1-Adrenergic Receptor–Induced Cardiac Hypertrophy

  2002cited by this paper
• Gene Ontology: tool for the unification of biology

  2000cited by this paper
• KEGG: Kyoto Encyclopedia of Genes and Genomes

  2000cited by this paper
• Contribution of hypoxia to the development of cardiomyopathy in hamsters.

  1997cited by this paper
• Vascular System Defects and Impaired Cell Chemokinesis as a Result of Gα13 Deficiency

  1997cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• The anthracyclines: will we ever find a better doxorubicin?

  1992cited by this paper
• Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

  1991cited by this paper
• Altered thyroid hormone metabolism in advanced heart failure.

  1990cited by this paper
• Intermittent Brief Periods of Ischemia Have a Cumulative Effect and May Cause Myocardial Necrosis

  1982cited by this paper

• Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis

  2025cites this paper
• Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association.

  2025cites this paper
• Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci

  2024cites this paper
• Investigation of Flavonoid Scaffolds as DAX1 Inhibitors against Ewing Sarcoma through Pharmacoinformatic and Dynamic Simulation Studies

  2023cites this paper
• Recent advances in GPR35 pharmacology; 5-HIAA serotonin metabolite becomes a ligand

  2023cites this paper
• Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk

  2023cites this paper
• Multi-omics integration analysis of GPCRs in pan-cancer to uncover inter-omics relationships and potential driver genes

  2023cites this paper
• Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children

  2023cites this paper
• Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

  2023cites this paper
• Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity: A case series

  2022cites this paper
• Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review

  2022cites this paper
• Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis

  2021cites this paper
• Long-Term Effects of Pediatric Acute Lymphoblastic Leukemia Chemotherapy: Can Recent Findings Inform Old Strategies?

  2021cites this paper
• Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer

  2020cites this paper
• Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy

  2020cites this paper
• Cardiovascular and Pulmonary Challenges After Treatment of Childhood Cancer.

  2020cites this paper
• Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity

  2020cites this paper
• Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology

  2020cites this paper
• hiPSCs in cardio-oncology: deciphering the genomics

  2019cites this paper
• Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling

  2019cites this paper
• The Orphan Receptor GPR35 Contributes to Angiotensin II–Induced Hypertension and Cardiac Dysfunction in Mice

  2018cites this paper
• GenePy - a score for estimating gene pathogenicity in individuals using next-generation sequencing data

  2018cites this paper
• Advanced modelling of genomic data in Inflammatory Bowel Disease

  2018cites this paper
• Overexpression of GPR35 confers drug resistance in NSCLC cells by β-arrestin/Akt signaling

  2018cites this paper
• Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients

  2017cites this paper